Fungemia due to Trichosporon asahii in a neutropenic child refractory to amphotericin B -: Clearance with voriconazole

被引：44
作者：
Antachopoulos, C
Papakonstantinou, E
Dotis, J
Bibashi, E
Tamiolaki, M
Koliouskas, D
Roilides, E
机构：
[1] Univ Arizona, Hippokratio Gen Hosp, Dept Pediat, Thessaloniki 54642, Greece
[2] Hippokratio Gen Hosp, Dept Pediat Oncol, Thessaloniki 54642, Greece
[3] Hippokratio Gen Hosp, Dept Microbiol, Thessaloniki 54642, Greece
[4] Hippokratio Gen Hosp, Pediat Intens Care Unit, Thessaloniki 54642, Greece
来源：
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY | 2005年 / 27卷 / 05期
关键词：
Trichosporon asahii; acute leukemia; voriconazole; amphotericin B;
D O I：
10.1097/01.mph.0000164865.70522.d7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Disseminated Trichosporon infection in neutropenic patients carries a poor prognosis. Clinical evidence on the use of voriconazole for this infection is limited. The authors report a case of Trichosporon asahii fungemia refractory to liposomal amphotericin B treatment in a boy with acute lymphoblastic leukemia, which resolved after the addition of voriconazole. Both voriconazole and amphotericin B exhibited low minimal inhibitory concentrations and minimal fungicidal concentrations, and their combination was indifferent in vitro. The use of voriconazole for the treatment of trichosporonosis in patients with hematologic malignancies deserves further study.
引用
收藏
页码：283 / 285
页数：3
相关论文
共 12 条
[1]   Trichosporon asahii infection treated with caspofungin combined with liposomal amphotericin B [J].
Bassetti, M ;
Bisio, F ;
Di Biagio, A ;
Pierri, I ;
Balocco, M ;
Soro, O ;
Cruciani, M ;
Bassetti, D .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 54 (02) :575-577
[2]   Multidrug-resistant Trichosporon asahii isolates are susceptible to voriconazole [J].
Falk, R ;
Wolf, DG ;
Shapiro, M ;
Polacheck, I .
JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (02) :911-911
[3]   Use of voriconazole to successfully treat disseminated Trichosporon asahii infection in a patient with acute myeloid leukaemia [J].
Fournier, S ;
Pavageau, W ;
Feuillhade, M ;
Deplus, S ;
Zagdanski, AM ;
Verola, O ;
Dombret, H ;
Molina, JM .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2002, 21 (12) :892-896
[4]   Combination antifungal therapy [J].
Johnson, MD ;
MacDougall, C ;
Ostrosky-Zeichner, L ;
Perfect, JR ;
Rex, JH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (03) :693-715
[5]   Voriconazole serum concentrations in an infant treated for Trichosporon beigelii infection [J].
Maples, HD ;
Stowe, CD ;
Saccente, SL ;
Jacobs, RF .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2003, 22 (11) :1022-1024
[6]  
NATIONAL COMMITTEE FOR CLINICAL LABORATORY STANDARDS-NCCLS, 1997, M27A NCCLS
[7]   In vitro antifungal susceptibilities of Trichosporon species [J].
Paphitou, NI ;
Ostrosky-Zeichner, L ;
Paetznick, VL ;
Rodriguez, JR ;
Chen, E ;
Rex, JH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (04) :1144-1146
[8]   In vitro activities of terbinafine in combination with fluconazole, itraconazole, voriconazole, and posaconazole against clinical isolates of Candida glabrata with decreased susceptibility to azoles [J].
Perea, S ;
Gonzalez, G ;
Fothergill, AW ;
Sutton, DA ;
Rinaldi, MG .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (05) :1831-1833
[9]   Antifungal pharmacodynamic characteristics of amphotericin B against Trichosporon asahii, using time-kill methodology [J].
Toriumi, Y ;
Sugita, T ;
Nakajima, M ;
Matsushima, T ;
Shinoda, T .
MICROBIOLOGY AND IMMUNOLOGY, 2002, 46 (02) :89-93
[10]  
Vasquez JA., 2003, CLIN MYCOLOGY, P206
12